Semaglutide 6mg ODT (30 day)

Semaglutide 6 mg ODT (30-day supply) is an orally disintegrating tablet formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide mimics endogenous GLP-1, a hormone that enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety, making it effective for type 2 diabetes management and weight loss. The 6 mg ODT is typically designed for once-weekly or daily dosing (depending on the formulation and clinical protocol), providing a convenient alternative to injectable GLP-1 therapies. Orally disintegrating tablets dissolve rapidly in the mouth, improving patient adherence and bypassing the need for subcutaneous injection. Semaglutide has demonstrated robust efficacy in reducing HbA1c, supporting weight loss, and improving cardiovascular risk factors in adults with type 2 diabetes or obesity: Clinical efficacy in type 2 diabetes and weight management: https://pubmed.ncbi.nlm.nih.gov/32809483/ Mechanism of GLP-1 receptor agonists: https://pubmed.ncbi.nlm.nih.gov/30108389/